SCHEMBL10120059

SCHEMBL10120059

CC(C)(C)C(=O)SCCOP(=O)(OCCSC(=O)C(C)(C)C)OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ccnn23)[C@H](O)[C@@H]1O

nearest known ligand 0.49

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS2 O15393 1/20 0.38
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ CA9 Q16790 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10120058 0.93 CA12 (0.37) TMPRSS2CA12CA1CA2CA9
SCHEMBL24119311 0.90 TMPRSS2 (0.43) TMPRSS2CA12CA1CA2CA9
SCHEMBL10120864 0.90 TMPRSS2 (0.43) TMPRSS2CA12CA1CA2CA9
SCHEMBL22646485 0.87 TMPRSS2 (0.42) TMPRSS2CA12CA1CA2CA9
SCHEMBL25821533 0.87 TMPRSS2 (0.36) TMPRSS2CA12CA1CA2CA9
SCHEMBL25821541 0.85 TMPRSS2 (0.47) TMPRSS2CA12CA1CA2CA9
SCHEMBL24976071 0.85 TMPRSS2 (0.40) TMPRSS2CA12CA1CA2CA9
SCHEMBL31684196 0.82 TMPRSS2 (0.42) TMPRSS2CA12CA1CA2CA9
SCHEMBL10120871 0.82 CA12 (0.36) TMPRSS2CA12CA1CA2CA9
SCHEMBL17719216 0.81 TMPRSS2 (0.44) TMPRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346812-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS GILEAD SCIENCES, INC. 2023-11-02 — — US disclosed
US-11660307-B2 Methods for treating SARS CoV-2 infections GILEAD SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 — — US disclosed
US-9949994-B2 Methods for treating Filoviridae virus infections GILEAD SCIENCES, INC. (US) 2018-04-24 — — US disclosed
US-9724360-B2 Methods for treating Filoviridae virus infections GILEAD SCIENCES, INC. (US) 2017-08-08 — — US disclosed
US-20170071964-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2017-03-16 — — US disclosed
US-20160361330-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-12-15 — — US disclosed
US-20160122374-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2016-05-05 — — US disclosed
US-20150152116-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2015-06-04 — — US disclosed
US-20150111839-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2015-04-23 — — US disclosed
US-20120027752-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. (US) 2012-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361330-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS PNP, PRPF4, RPIA TMPRSS2 1951/4885CA12 2049/4885CA1 4046/4885
US-20150111839-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 TMPRSS2 433/4885CA12 1157/4885CA1 2558/4885
US-20120027752-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 TMPRSS2 433/4885CA12 1157/4885CA1 2558/4885
US-20150152116-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 TMPRSS2 433/4885CA12 1157/4885CA1 2558/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 TMPRSS2 433/4885CA12 1157/4885CA1 2558/4885
US-11660307-B2 Methods for treating SARS CoV-2 infections ACE2, ACE, PNP TMPRSS2 6/4885CA12 770/4885CA1 3405/4885
US-20170071964-A1 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS ACE, PNP, ACE2 TMPRSS2 12/4885CA12 2132/4885CA1 2531/4885
US-20230346812-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS ACE2, ACE, PNP TMPRSS2 6/4885CA12 770/4885CA1 3405/4885
US-20160122374-A1 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS PNP, PRPF4, RPIA TMPRSS2 1951/4885CA12 2049/4885CA1 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback